SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: glass 0.5 full who wrote (4226)4/28/2016 5:59:56 PM
From: Biomaven  Read Replies (1) of 4474
 
>>no non-oncogenic instance of ALK

That's kind of beside the point because all "targeted" TKI's in fact have some level of off-target impact. Some indeed (like Iclusig) are fairly promiscuous and hit literally dozens of other targets at relevant doses. As you increase the dose, so more and more other pathways get impacted along the way.

For the new drug, we still don't know if it's EGFR that will be the dose-limiting factor. Remember that the very successful first-gen drugs in this class do hit wild-type EGFR at relevant doses - hence the skin rash.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News